SK bioscience Co.,Ltd.
KRX:302440.KS
46250 (KRW) • At close July 30, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 267,545.049 | 369,505.556 | 456,725.871 | 929,000.93 | 225,610.785 | 183,937.702 | 88,173.588 |
| Cost of Revenue
| 236,569.373 | 227,681.203 | 217,114.93 | 358,717.803 | 130,268.716 | 106,078.005 | 48,958.069 |
| Gross Profit
| 30,975.676 | 141,824.353 | 239,610.941 | 570,283.127 | 95,342.069 | 77,859.697 | 39,215.519 |
| Gross Profit Ratio
| 0.116 | 0.384 | 0.525 | 0.614 | 0.423 | 0.423 | 0.445 |
| Reseach & Development Expenses
| 71,352.814 | 85,743.416 | 57,959.645 | 47,250.075 | 25,987.1 | 27,719.663 | 10,512.411 |
| General & Administrative Expenses
| 8,690.867 | 6,964.608 | 5,618.648 | 4,167.364 | 2,371.832 | 2,393.608 | 1,123.199 |
| Selling & Marketing Expenses
| 32,207.205 | 18,382.898 | 21,698.477 | 11,571.726 | 10,458.567 | 10,966.635 | 5,914.201 |
| SG&A
| 40,898.072 | 25,347.506 | 27,317.125 | 15,739.09 | 12,830.399 | 13,360.243 | 7,037.4 |
| Other Expenses
| 57,156.088 | 0 | 39,320.554 | 33,074.106 | 18,814.122 | 13,983.272 | -480.806 |
| Operating Expenses
| 169,406.974 | 146,555.341 | 124,597.324 | 96,063.271 | 57,631.621 | 55,063.178 | 24,008.862 |
| Operating Income
| -138,431.298 | -4,730.988 | 115,013.618 | 474,219.856 | 37,710.447 | 22,796.519 | 15,206.658 |
| Operating Income Ratio
| -0.517 | -0.013 | 0.252 | 0.51 | 0.167 | 0.124 | 0.172 |
| Total Other Income Expenses Net
| 49,324.47 | 12,058.215 | 26,719.564 | -3,091.676 | -417.194 | -4,311.247 | -14,342.668 |
| Income Before Tax
| -89,106.828 | 7,327.227 | 141,733.182 | 471,128.181 | 37,293.253 | 18,485.273 | 863.99 |
| Income Before Tax Ratio
| -0.333 | 0.02 | 0.31 | 0.507 | 0.165 | 0.1 | 0.01 |
| Income Tax Expense
| -38,989.758 | -14,990.492 | 19,281.233 | 115,988.904 | 4,403.541 | 3,807.868 | 443.146 |
| Net Income
| -53,881.199 | 22,317.719 | 122,451.95 | 355,139.277 | 32,889.712 | 14,677.405 | 420.845 |
| Net Income Ratio
| -0.201 | 0.06 | 0.268 | 0.382 | 0.146 | 0.08 | 0.005 |
| EPS
| -700.16 | 291 | 1,596.18 | 4,642.34 | 429.93 | 3,597.82 | 209.93 |
| EPS Diluted
| -701.32 | 289.79 | 1,589.84 | 4,642.34 | 429.93 | 3,597.82 | 209.93 |
| EBITDA
| -36,196.684 | 43,490.069 | 142,250.027 | 492,995.161 | 57,971.384 | 37,213.073 | 21,109.42 |
| EBITDA Ratio
| -0.135 | 0.118 | 0.311 | 0.531 | 0.257 | 0.202 | 0.239 |